Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + mitomycin C + vindesine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of etoposide, mitomycin C, and vindesine—commonly referred to as the MEV regimen—is a chemotherapeutic protocol used primarily in the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC). Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks and inhibits DNA synthesis. Mitomycin C is an alkylating agent that crosslinks DNA, leading to inhibition of DNA replication and cell death. Vindesine is a vinca alkaloid that disrupts microtubule formation, thereby inhibiting mitosis. The MEV regimen has demonstrated activity in NSCLC with moderate response rates and manageable toxicity profiles[1][2].
- Other names
- MEV regimen
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on etoposide + mitomycin C + vindesine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + mitomycin C + vindesine.